CD36 and malaria: Recent data provide evidence that rosiglitazone PPARγ ligand can in vitro and in vivo improves the outcome of experimental malaria in mice, enhancing CD36-mediated PEs phagocytic processes and limiting parasite-induced inflammatory processes [9].